Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone
replacement therapy. Menopause.1999;6:282-289.
Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Intern Med.1995;122:9-16.
Michaelsson K, Baron JA, Farahmand BY.
et al. Hormone replacement therapy and the risk of hip fracture: population-based
Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk of first hip fracture. Ann Intern Med.1990;113:95-103.
Mosekilde L, Beck-Nielsen H, Sorensen OH.
et al. Hormonal replacement therapy reduces forearm fracture incidence in
recent postmenopausal women: results of the Danish Osteoporosis Prevention
Lufkin EG, Wahner HW, O'Fallon WM.
et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med.1992;117:1-9.
Windeler J, Lange S. Events per person year: a dubious concept. BMJ.1995;310:454-456.
Hulley S, Grady D, Bush T.
et al. Randomized trial of estrogen and progestin for secondary prevention
of coronary heart disease in postmenopausal women. JAMA.1998;280:605-613.
Komulainen MH, Kroger H, Tuppurainen MT.
et al. HRT and Vit D in prevention of non-vertebral fractures in posmenopausal
women: a 5-year randomised trial. Maturitas.1998;31:45-54.
Fitzpatrick LA, Litin SC, Bell MR. The Women's Health Initiative: a heart-to-HRT conversation. Mayo Clin Proc.2000;75:559-561.
Barrett-Connor E. Hormone replacement therapy. BMJ.1998;317:457-461.
Eddy DM, Johnston CC, Cummings SR.
et al. Osteoporosis: cost-effectiveness analysis and review of the evidence
for prevention, diagnosis and treatment. Osteoporos Int.1998;(suppl 4):1-88.
Reginster J-Y, Bruyere O, Audran M.
et al. Do estrogens effectively prevent osteoporosis-related fractures? Calcif Tissue Int.2000;67:191-194.
Royal College of Physicians. Clinical Guidelines for the Prevention and Treatment
of Osteoporosis. London, England: Royal College of Physicians; 1999.
Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and
cancer: pooled data from clinical trials. BMJ.1997;315:149-153.
Moher D, Cook DJ, Jadad AR.
et al. Assessing the quality of reports of randomized trials: implications
for the conduct of meta-analysis. Health Technol Assess.1999;3:1-98.
Thompson SG. Systematic review: why sources of heterogeneity in meta-analysis should
be investigated. BMJ.1994;309:1351-1355.
Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman M. Estrogen Replacement Therapy I: a 10-year prospective study in the
relationship to osteoporosis. Obstet Gynecol.1979;53:277-281.
Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement therapy
and bisphosphonate, alone or in combination, in women with postmenopausal
osteoporosis. Am J Med.1998;104:219-226.
Alexandersen P, Riis BJ, Christiansen C. Monoflurophosphate Combined with hormone replacement therapy induces
a synergistic effect on bone mass by dissociating bone formation and resoprtion
in postmenopausal women: a randomized study. J Clin Endocrinol Metab.1999;84:3013-3020.
Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after
Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol
for preventing postmenopausal bone loss. Obstet Gynecol.1999;94:330-336.
Eiken P, Nielsen SP, Kolthoff N. Effects on bone mass after eight years of hormonal replacement therapy. Br J Obstet Gynaecol.1997;104:702-707.
Ravn P, Bidstrup M, Wasnich RD.
et al. Alendronate and estrogen-progestin in the long-term prevention of bone
loss: four-year results from the Early Postmenopausal Intervention Cohort
Study. Ann Intern Med.1999;131:935-942.
The Writing Group for the PEPI Trial. Effect of hormone therapy on bone mineral density. JAMA.1996;276:1389-1396.
Herrington DM, Reboussin DM, Broshnihan KB.
et al. Effects of estrogen replacement on the progression of coronary-artery
atherosclerosis. N Engl J Med.2000;343:522-529.
Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR. Effects of hormone replacement therapy on bone mineral density in postmenopausal
women with primary hyperparathyroidism. Arch Intern Med.2000;160:2161-2166.
Mulnard RA, Cotman CW, Kawas C.
et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer
disease: a randomized controlled trial. JAMA.2000;283:1007-1015.
Genant HK, Lucas J, Weiss S.
et al. for the Estratab/Osteoporosis Study Group. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol
concentrations, endometrium, and lipid levels. Arch Intern Med.1997;157:2609-2615.
Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy
with calcium and vitamin D on bone in elderly women: a randomized, controlled
trial. Ann Intern Med.1999;130:897-904.
Delmas PD, Confavreux E, Ganero P.
et al. A combination of low doses of 17b-estradiol and norethisterone acetate
prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int.2000;11:177-187.
Bjarnson NH, Christiansen C. Early response in biochemical makers predicts long-term response in
bone mass during hormone replacement therapy in early postmenopausal women. Bone.2000;26:561-569.
Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol.1990;76:290-295.
Cheng S, Sipila S, Puolakka H, Suominen H. Effects of hormone replacement therapy and high impact physical exercise
on bone/muscle ratio in postmenopausal women. Osteoporos Int.2000;11(suppl 2):175.
Stevenson JC, Lees B. Bone conserving effects of oestrogen are dose-dependent for age and
time since menopause. Osteoporos Int.2000;11(suppl 1):25.
Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement
therapy with estradiol-17B and dydrogesterone. Osteoporos Int.2001;12:251-258.
Gallagher JC, Fowler S. Effect of estrogen, calcitriol and a combination of estrogen and calcitriol
on bone mineral density and fractures in elderly women. J Bone Miner Res.1999;14(suppl 1):209.
Cohen FJ, Eckert S, Mitlak BH. Geographic differences in bone turnover: data from a multinational
study in healthy postmenopausal women. Calcif Tissue Int.1998;63:277-282.
Freedman M, San Martin J, O'Gorman J.
et al. Digitized mammography: a clinical trial of postmenopausal women randomly
assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst.2001;93:51-56.
Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal
radius: a case-control study. Lancet.1979;2:705-709.
Michaelsson K, Baron JA, Johnell O, Persson I, Ljunghall S. Variation in the efficacy of hormone replacement therapy in the prevention
of hip fracture. Osteoporos Int.1998;8:540-546.
Cauley JA, Black DM, Barrett-Connor E.
et al. Effects of hormone replacement therapy on clinical fractures and height
loss: the Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med.2001;110:442-450.
Black DM, Cummings SR, Karpf DB.
et al. Randomised trial of effect of alendronate on risk of fracture in women
with existing vertebral fractures. Lancet.1996;348:1535-1541.
McClung MR, Geusens P, Miller PD.
et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med.2001;344:333-340.
Ismail AJ, O'Neil TW, Cockerill W.
et al. Validity of self-reported fractures: results from a prospective study
in men and women across Europe. Osteoporos Int.2000;11:248-254.